瑞丰高材 reported revenue of ¥1.10B for the period ended 2026-06-30, +9.0% year on year. Net income was ¥0.06B, a 5.3% net margin on a 18.9% gross margin. The largest revenue line is ACR助剂 at 45% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.10B | +9.0% |
| Gross profit | ¥0.21B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.06B | +358.6% |
| Gross margin | 18.9% | Net margin 5.3% |
| Revenue Q/Q | +10.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| ACR助剂 | ¥0.49B | 44.9% |
| MBS抗冲改性剂 | ¥0.40B | 36.6% |
| MC抗冲改性剂 | ¥0.10B | 9.1% |
| 工程塑料助剂 | ¥0.10B | 8.7% |
| 其他 | ¥0.01B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.89B | 81.1% |
| R&D | ¥0.00B | 0.3% |
| SG&A | ¥0.11B | 10.2% |
| Tax & other | ¥0.01B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥2.33B |
| Total liabilities | ¥0.78B |
| Shareholders' equity | ¥1.55B |
| Equity / assets | 66.4% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 11% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康 ・ 初灵信息 ・ 金信诺 ・ 卫宁健康 ・ 仟源医药 ・ 常山药业 ・ 星星科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies